智通财经APP讯，昭衍新药(06127)公布，公司原副董事长左从林(已离任)因自身资金需求，计划根据市 场价格情况，自本公告披露之日起 3 个交易日后即 2025 年 8 月 19 日至 2025 年 8 月 29 日内通过集中竞 价或大宗交易的方式减持其所持有公司股份不超过352.45万股，减持比例不超过公司总股本的 0.4703%，减持计划实施期间，公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减 持数量将进行相应调整。 （原标题：昭衍新药(06127)股东左从林拟减持公司股份不超过352.45万股） ...

昭衍新药公告，原副董事长左从林因自身资金需求，计划根据市场价格情况，自本公告披露之日起3个 交易日后即2025年8月19日至2025年8月29日内，通过集中竞价或大宗交易的方式减持其所持有公司股份 不超过3524500股，减持比例不超过公司总股本的0.4703%。 (本文来自第一财经) ...

昭衍新药（603127）(06127)公布，公司原副董事长左从林(已离任)因自身资金需求，计划根据市场价格 情况，自本公告披露之日起3个交易日后即2025年8月19日至2025年8月29日内通过集中竞价或大宗交易 的方式减持其所持有公司股份不超过352.45万股，减持比例不超过公司总股本的0.4703%，减持计划实 施期间，公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调 整。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年8月13日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

Core Viewpoint - Zhaoyan New Drug (603127) has seen a significant stock price increase of 9.23%, reaching HKD 24.62, with a trading volume of HKD 391 million, indicating positive market sentiment towards the company [1] Company Analysis - Huatai Securities reports that after experiencing high growth from 2018 to 2022, Zhaoyan New Drug is expected to face order volume and price pressures from 2023 to 2025, but these negative factors are gradually being resolved. Starting in 2026, the company is anticipated to enter a new growth phase driven by domestic recovery and offshore outsourcing [1] - The price of experimental monkeys, a key indicator of supply and demand in the safety evaluation industry, is currently stable at RMB 80,000 to 100,000 per monkey, with a slight upward trend expected as supply-demand dynamics tighten [1] - The report suggests that as the supply-demand gap widens, monkey prices may enter a new upward cycle, having previously reached RMB 150,000 to 200,000 per monkey in 2022 [1] Industry Outlook - Contrary to market concerns regarding the impact of new FDA regulations and the growth potential of overseas business, Huatai Securities believes that the new regulations are primarily focused on the monoclonal antibody sector and have not yet been adopted domestically. In the short term, animal testing will remain the dominant method in global drug safety evaluation for the next 3 to 5 years [1] - Long-term prospects for new methodologies, such as AI and organoids, remain uncertain and will require careful evaluation of transitional results and technological maturity [1] - The report expresses optimism about the collaborative evolution of animal testing and new methodologies, which could drive overall industry development, and highlights the company's proactive positioning in adopting new methodologies to enhance its comprehensive capabilities [1]

Core Viewpoint - Zhaoyan New Drug (06127) has seen a significant stock price increase of over 9%, currently trading at 24.62 HKD, with a transaction volume of 391 million HKD, indicating positive market sentiment towards the company [1] Group 1: Company Performance and Outlook - Huatai Securities reports that Zhaoyan New Drug experienced high growth from 2018 to 2022, but is facing order volume and price pressures from 2023 to 2025. However, starting in 2026, the company is expected to enter a new growth phase driven by domestic recovery and overseas outsourcing [1] - The report highlights that the price of experimental monkeys, a key indicator of supply and demand in the safety evaluation industry, is currently stable at 80,000 to 100,000 RMB per monkey, with a potential upward trend as supply-demand gaps widen [1] Group 2: Market Concerns and Long-term Perspectives - Contrary to market concerns regarding the impact of FDA new policies and overseas business growth potential, Huatai Securities believes that the new policies are primarily focused on monoclonal antibodies and have not yet been adopted domestically. Animal testing will remain the dominant method in global drug safety evaluation for the next 3-5 years [1] - The long-term application of new methodologies such as AI and organoids is still uncertain, requiring careful consideration of transitional results and technological maturity. The company is expected to enhance its overall capabilities through proactive engagement with new methodologies [1]

天眼查商业履历信息显示，北京昭衍新药研究中心股份有限公司，成立于1998年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本53564.4275万人民币，实缴资本4560.33万人民币。公 司法定代表人为冯宇霞。 通过天眼查大数据分析，北京昭衍新药研究中心股份有限公司共对外投资了20家企业，参与招投标项目 44次，知识产权方面有商标信息70条，专利信息54条，此外企业还拥有行政许可44个。 来源：金融界 资金流向方面，今日主力资金净流入2.27亿元，占比成交额12.81%。其中，超大单净流入1.99亿元、占 成交额11.25%，大单净流入2752.09万元、占成交额1.55%，中单净流出流出8315.43万元、占成交额 4.7%，小单净流出14356.95万元、占成交额8.11%。 昭衍新药最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少11.54%，归属净利 润4111.95万元，同比增长115.11%，扣非净利润2566.26万元，同比增长109.14%，流动比率4.613、速动 比率3.221、资产负债率13.96%。 金融界消息 截至2025年8月13日收盘， ...

Group 1 - The National Medical Insurance Administration has approved 534 drugs for the basic medical insurance drug list, a significant increase compared to 2024, and established a new commercial insurance innovative drug list with 121 drugs [4] - The biopharmaceutical ETF (159839) has seen a strong performance, with a 2.53% increase on August 13, 2025, and a 1-month cumulative increase of 8.26% [1][4] - Leveraged funds are actively investing in the biopharmaceutical sector, with the latest financing buy amount reaching 2.34 million yuan and a financing balance of 12.62 million yuan [4] Group 2 - The biopharmaceutical ETF has experienced a significant increase in shares, with a growth of 6 million shares over the past year, ranking in the top third among comparable funds [3] - The biopharmaceutical sector remains a key focus in the pharmaceutical industry, with ongoing significant business development (BD) transactions that enhance resource integration and project development [5] - Recent global transactions in innovative drugs indicate a vibrant market, with six key transactions reported, reflecting the active collaboration between domestic and international companies [4]

Group 1 - The CRO (Contract Research Organization) sector is experiencing a rebound, with notable stock price increases among key players [1] - Zhaoyan New Drug has reached its daily limit increase, indicating strong market interest and confidence [1] - Other companies in the sector, including Medisi, Kailaiying, Minophagen, Sunshine Nuohe, WuXi AppTec, and Kanglong Huacheng, have also seen significant stock price increases [1]

Core Viewpoint - The company, Zhaoyan New Drug, has shown a significant increase in net profit despite a decline in revenue, indicating potential resilience in its business model within the pharmaceutical services industry [1][2]. Company Summary - Zhaoyan New Drug's closing price on August 11 was 31.22 yuan, reflecting a 3.38% increase, with a rolling PE ratio of 60.40 times and a total market capitalization of 23.399 billion yuan [1]. - The company operates primarily in non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1]. - For the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. Industry Summary - The average PE ratio for the medical services industry is 48.03 times, with a median of 60.62 times, positioning Zhaoyan New Drug at the 29th rank within the industry [1][2]. - The company is among 17 institutions holding shares, with a total of 10.9687 million shares valued at 231 million yuan [1].